Furthermore, as shown in Fig. 6a–d, we validated that targeting AMPK/ULK1 pathway enhanced TMZ-sensitivity in TS-GBM cells co-treated with PD-L1-ex and high-dose TMZ. Here, PRKAA1 is linked to glioblastoma.